

## Enhancing action of positive allosteric modulators through the design of dimeric compounds

Thomas Drapier, Pierre Geubelle, Charlotte Bouckaert, Lise Nielsen, Saara Laulumaa, Eric Goffin, Sébastien Dilly, Pierre Francotte, Julien Hanson, Lionel Pochet, Jette Sandholm Kastrup, and Bernard Pirotte

*J. Med. Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.8b00250 • Publication Date (Web): 18 May 2018

Downloaded from <http://pubs.acs.org> on May 18, 2018

### Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



# Enhancing action of positive allosteric modulators through the design of dimeric compounds

*Thomas Drapier<sup>1</sup>, Pierre Geubelle<sup>1,2</sup>, Charlotte Bouckaert<sup>3</sup>, Lise Nielsen<sup>4</sup>, Saara Laulumaa<sup>4</sup>,  
Eric Goffin<sup>1</sup>, Sébastien Dilly<sup>1</sup>, Pierre Francotte<sup>1</sup>, Julien Hanson<sup>1,2\*</sup>, Lionel Pochet<sup>3\*</sup>, Jette  
Sandholm Kastrup<sup>4\*</sup>, Bernard Pirotte<sup>1\*</sup>*

<sup>1</sup> Laboratory of Medicinal Chemistry, Center for Interdisciplinary Research on Medicines (CIRM), ULiège, Quartier  
Hôpital – Avenue Hippocrate, 15, B36, B-4000 Liège, Belgium

<sup>2</sup> Laboratory of Molecular Pharmacology, GIGA- Molecular Biology of Diseases, ULiège, B34, Quartier Hôpital –  
Avenue de l'hôpital, 11, B-4000 Liège, Belgium

<sup>3</sup> Namur Medicine & Drug Innovation Center (NAMEDIC), NARILIS, UNamur, rue de Bruxelles 61, B-5000  
Namur.

<sup>4</sup> Biostructural Research, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences,  
University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark

## Keywords

AMPA receptor; positive allosteric modulator; dimeric compound; crystallography; molecular  
modeling

## Abstract

The present study describes the identification of highly potent dimeric 1,2,4-benzothiadiazine 1,1-dioxide (BTD)-type positive allosteric modulators of the AMPA receptors (AMPApams) obtained by linking two monomeric BTD scaffolds through their respective 6-positions. Using previous X-ray data from monomeric BTDs co-crystallized with the GluA2<sub>o</sub> ligand-binding domain (LBD), a molecular modeling approach was performed to predict the preferred dimeric combinations. Two 6,6-ethylene-linked dimeric BTD compounds (**16** and **22**) were prepared and evaluated as AMPApams on HEK293 cells expressing GluA2<sub>o</sub>(Q) (calcium flux experiment). These compounds were found to be about 10,000 times more potent than their respective monomers, the most active dimeric compound being the bis-4-cyclopropyl-substituted compound **22** [6,6'-(ethane-1,2-diyl)bis(4-cyclopropyl-3,4-dihydro-2*H*-1,2,4-benzothiadiazine 1,1-dioxide)], with an EC<sub>50</sub> value of 1.4 nM. As a proof of concept, the bis-4-methyl-substituted dimeric compound **16** (EC<sub>50</sub> = 13 nM) was successfully co-crystallized with the GluA2<sub>o</sub>-LBD and was found to occupy the two BTD binding sites at the LBD dimer interface.

## Introduction

It is well established that L-glutamate is the key excitatory neurotransmitter in the central nervous system (CNS).<sup>1</sup> L-glutamate exerts its biological effect on the CNS through the activation of either metabotropic (mGluRs, G protein-coupled) or ionotropic (iGluRs, ligand-gated ion channel) receptors.<sup>1,2</sup> iGluRs can be classified into three subcategories depending on their affinity toward non-endogenous ligands: *N*-methyl-D-aspartic acid (NMDA) receptors,  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and kainic acid (KA)

receptors.<sup>1,2</sup> Due to rapid response to L-glutamate in the synapses, iGluRs play a sustainable role in the fast transmission of excitatory potentials from one neuron to another.<sup>3-5</sup> Several studies have shown the impact of a decrease of the AMPA signaling in brain disorders such as attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, mild depression or schizophrenia.<sup>6-8</sup> Based on this, the AMPA receptors (AMPA receptors) seem to be an interesting pharmacological target for the development of either probing tools or cognitive enhancers.

It is conceivable that agonists could be used as cognitive enhancers but their development is questioned due to the possible occurrence of unwanted and adverse phenomena related to excitotoxicity.<sup>9</sup> Therefore, AMPA positive allosteric modulators (so-called "AMPApams") have been postulated to be a more promising option. Because they do not bind into the orthosteric-binding site but into an allosteric binding site, they are expected to be devoid of an intrinsic activity on the AMPARs and to show an effect only when glutamate is released in the synapse. This mode of action is assumed to give better fine-tuning of the AMPA receptor signaling and to avoid the excitotoxicity problems resulting from overdose of a direct agonist.

AMPA receptors consist of various combinations of four different subunits (GluA1-4) that can bind to each other in several ways, either on a homo- or a heteromeric scaffold with heteromeric constructions preferred in wild type neurons.<sup>10</sup> They first assemble in homomeric dimers and then in functional dimers of dimers (homodimers or heterodimers).<sup>11</sup> Each subunit constituting the receptors can be divided into four semiautonomous domains.<sup>12-14</sup> Two of them are extracellular: the amino-terminal domain (ATD) and the ligand-binding domain (LBD). One is inside the membrane, which constitutes the channel itself, the transmembrane domain (TMD). The last one is intracellular, the carboxy-terminal domain (CTD).<sup>12-14</sup> Interactions with ligands occur at the level of the LBD, either with L-glutamate or with different allosteric modulators,

respectively in the orthosteric (agonist) binding site and in the allosteric binding site, which lies at the interface of two subunits.<sup>2</sup> The interactions of AMPApams with the AMPAR can lead to two main outcomes: they can act on slowing down the receptor deactivation process by enhancing the affinity of L-glutamate for its orthosteric binding site or they can increase the affinity between subunits, thereby inhibiting the receptor desensitization process, where conformational changes lead to the closure of the channel even if L-glutamate is still bound.<sup>15-17</sup>

The well-known allosteric binding site has a U shape and comprises LBDs of both subunits. It is divided in three smaller subsites called A, B/B' and C/C'.<sup>18,19</sup> Allosteric modulators interact with the different subsites depending on their chemical structure. For example, the benzamide-type family of AMPApams was shown to interact mostly with the A subsite.<sup>18</sup> Among those compounds, aniracetam (**1**, Figure 1) is referred to as the oldest molecule acting as an AMPApam.<sup>20</sup> The second major chemical class of AMPApams is the ring-fused thiadiazine family of compounds among which the benzothiadiazine dioxide (BTD) members are the most prominent representatives.<sup>20</sup> They were studied following the discovery of the *in vitro* AMPAR potentiation by cyclothiazide (**2**, Figure 1), a compound used in clinical practice for its diuretic action.<sup>21</sup> However, this drug did not show marked *in vivo* activity on the CNS resulting from AMPAR potentiation, probably because of its inability to cross the blood-brain barrier (BBB).<sup>18,20</sup> Cyclothiazide interacts with the B and C subsites of this allosteric binding site in a symmetrical way resulting in an interaction of one molecule per subunit, thus two molecules at the dimer interface.<sup>18</sup> Unlike cyclothiazide, IDRA 21 (**4**, Figure 1), a saturated analog of the potassium channel opener diazoxide (**3**, Figure 1), was found to be active *in vitro* as an AMPApam<sup>22</sup> and was further identified *in vivo* as a cognitive enhancer in animal models of cognitive impairments.<sup>23,24</sup> Accordingly, many examples of ring-fused thiadiazine dioxides

based on this structure were developed as AMPApams (see for example compounds **5-8**; Figure 1).<sup>20,25</sup> These molecules interact in different ways with the binding site compared to cyclothiazide: being smaller, they rotate in the cavity and only interact with the hydrophobic C/C' subsites (still with a ratio of one molecule per subunit, thus two molecules per dimer interface).<sup>18</sup> Recently, the large-sized BTD modulator **8** (BPAM538) was found to bind the "BTB" allosteric site with a high affinity and with only one molecule per dimer interface.<sup>26</sup> Other families of AMPApams that have their own way to interact with the allosteric binding site have been reported,<sup>20</sup> among which are *N*-biaryl(cyclo)alkyl-2-propanesulfonamides, phenyliminothiazoles and 3-trifluoromethylpyrazoles.

Among the reported AMPApams, *N*-biarylpropylmethanesulfonamides such as **9** synthesized by Kaae *et al.*<sup>27</sup> should be highlighted as the first examples of dimeric molecules modulating the activity of AMPARs. The authors showed that some dimeric compounds acted as AMPApams with a drastic one thousand fold elevation of the potency compared to the constitutive monomers.<sup>27</sup> This gain of potency was tentatively explained by the presence of the two-fold pattern fitting in the two subsites, C and C', on both side of the AMPAR dimer interface.

Based on X-ray data obtained from some examples of BTB-type AMPApams synthesized by our team and co-crystallized with the GluA2<sub>o</sub>-LBD,<sup>28-33</sup> we clearly observed a close proximity of two modulators in two binding sites at the dimer interface. Thus, we hypothesized that it should be possible to design dimeric compounds linked together *via* the 6-position of the respective BTB monomers (Figure 2), providing new ligands with a significant enhancement of potency on AMPARs. This assumption was reinforced by our recent work on 7-phenoxy-substituted BTBs.

<sup>26</sup> Indeed, we demonstrated that these compounds occupied the C subsite with their BTB moiety, spanning the A subsite and pointing the methoxy substituent toward the B' subsite where water-

mediated interactions took place between receptor subunits.<sup>26</sup> Therefore, we reasoned that it could be possible to design rather large molecules that would interact on both sites of the GluA2<sub>o</sub>-LBD dimer interface. Starting from such hypothesis, we elaborated our work with an initial molecular modeling approach (docking studies) to predict what would be the most potent dimeric modulator candidates. These molecules were synthesized, pharmacologically evaluated and then compared to their respective monomers in order to demonstrate a gain of activity on the AMPAR by the design of dimeric compounds, and finally co-crystallized with the GluA2<sub>o</sub>-LBD as an ultimate proof of concept.

## **Results and Discussion**

### ***Dimeric compounds design based on docking studies***

In order to prioritize the synthesis of novel compounds, we decided to dock potential dimeric combinations and to compare the obtained results with the position of the two isolated monomers (compound **6**) in the crystal structure (pdb-code 4N07).<sup>29</sup> According to the distance between the two monomers in the crystal structure, we estimated that an ethylene or a propylene spacer would be appropriate to generate dimeric structures. The anchoring points for the linker were set to the 6,6-, 7,7- or 6,7-positions. We also considered amide or methylamine linkers instead of the alkyl-linking group. The alkyl substituent at the 4-position was chosen in accordance with previously established structure-activity relationships (SAR) (a methyl radical as the smallest alkyl group and a cyclopropyl radical known to confer the highest potency in the BTB series of AMPA-pams). Finally, we evaluated the possibility to simplify the structure by replacing one of the BTB monomers by a simpler benzenesulfonamide group. On this ground, a total of 10

potential dimeric compounds were designed and docked using the automated GOLD 5.3.0 program while the binding energy and interactions were obtained using Discovery Studio 4.0. The docking solutions were ranked and analyzed according to the occurrence of compounds in each cluster, the ChemPLP score, the calculated binding energy and the superimposition with compound **6** in the crystal structure (see Supporting Information for details on the interactions between the docking pose and the target).

From the results of this docking study, it seems that an ethylene linker would be more favorable compared to a propylene, an amide or a methylamine linker, and that the anchoring point should preferably be the 6,6-position (Table 1). While a propylene linker associated to a *N*-methyl moiety gives a promising calculated binding energy, its superimposition with the monomer in the crystal structure was found to be less satisfactory (see dimeric compounds C and D in the Supporting Information). The simplification of the dimeric structure through the replacement of one BTM monomer with a benzenesulfonamide group led to a marked decrease of estimated binding energy. Taken together, the results of this analysis highlighted the potential interest of the dimeric compounds A (**16**) and B (**22**) with an ethylene bridge between the two 6-positions of the respective BTM scaffolds for potent AMPAR positive allosteric modulation.

### *Synthesis of the target compounds*

The synthetic pathways giving access to the two desired dimeric molecules **16** and **22** are shown in Schemes 1 and 2. It should be noted that the change of the nature of the substituent on the nitrogen atom at the 4-position led to a complete change in the synthetic pathway. For the 4-methyl-substituted dimeric compound **16**, a classical convergent method was used and we firstly



realized the synthesis of the monomeric BTD intermediate **14** according to previously described protocols<sup>29</sup> except the use of a Suzuki's coupling reaction for vinylation at the 6-position. Finally, the 6-vinyl-substituted monomer **14** was coupled through a Grubbs' metathesis for dimerization to obtain the dimeric intermediate **15**, which gave access to the final compound **16** after hydrogenation (Scheme 1). For the 4-cyclopropyl-substituted dimeric molecule **22** the same synthetic pathway was investigated, but the classical ring formation with triethyl orthoformate on intermediate **18** led to uncharacterized byproducts. A second pathway was developed in which the dimerization took place before the ring closure reaction, and then the benzothiadiazine dioxide cycle was obtained on both sides of the dimeric molecule according to classical protocols (Scheme 2).

Concerning the monomeric compounds selected for comparison purposes in this work, the BTDs **34** and **35** devoid of a substituent at the 6-position were synthesized as previously described.<sup>29,34</sup> The corresponding 6-methyl-substituted BTDs **28** and **33** were obtained using a slightly modified pathway compared to their corresponding unsubstituted analogs at the 6-position (Schemes 3 and 4).

Starting from *m*-toluidine (**23**), the ring closure reaction was performed with chlorosulfonyl isocyanate in the classical experimental conditions described by Girard *et al.*<sup>35</sup> The reaction provided a mixture of two geometric isomers (**24a** and **24b**) (Scheme 3). The mixture was engaged in the next step of hydrolysis by means of concentrated sulfuric acid in water (50% w/v). After 6 hours at refluxing temperature, compound **24b** was predominantly converted into the corresponding ring-opened aminobenzenesulfonamide **25**, while compound **24a** remained largely insoluble and unaffected in the acidic medium. After filtration, compound **25** was

recovered in the filtrate, and then engaged in the next usual steps<sup>34</sup> up to the target compound **28** (Scheme 3).

For the synthesis of **33**, starting compound 2-fluoro-4-methylaniline (**29**) was converted into the corresponding 2-fluoro-4-methylbenzenesulfonamide **30** after diazotization according to the Meerwein conditions.<sup>36</sup> The *o*-fluorobenzenesulfonamide **30** was then converted to the target compound **33** according to a multistep sequence previously described for 4-cyclopropyl-substituted 3,4-dihydro-2*H*-1,2,4-benzothiadiazine 1,1-dioxides (scheme 4).<sup>29</sup>

### *Dramatic increase of the potency of AMPApams by the dimeric design*

The evaluation of the two dimeric molecules **16** and **22** and their constitutive monomers **28**, **33**, **34** and **35** as AMPApams was achieved with a fluorescence-based calcium assay as previously described.<sup>26</sup> HEK293 cells stably expressing GluA2<sub>o</sub>(*Q*) were loaded with the calcium-sensitive fluorescent probe Fluo-4-AM. The cells were incubated with the modulators at different concentrations and stimulated with L-glutamate (1 mM).<sup>37</sup> The intensity of fluorescence emission is positively correlated to the cytoplasmic concentration of calcium ions and hence can be used as a surrogate measure to estimate the calcium influx from extracellular medium through the open AMPAR channel. Therefore, this assay is suitable to determine the potentiating activity of the compounds on the L-glutamate-induced AMPAR opening. From the data obtained, the pEC<sub>50</sub> values (negative logarithm of the modulator concentration responsible for 50% of the maximum effect) were calculated for the six selected molecules and compared with the pEC<sub>50</sub> values obtained in the same conditions for the reference compounds **6** and **8** (Table 2; Figure 3).

As expected from previous SAR studies on BTD-type AMPApams,<sup>20,25</sup> the cyclopropyl substituent at the 4-position was always found to be the optimal (cyclo)alkyl chain with a gain of potency compared to the corresponding 4-methyl-substituted compounds of at least one log unit (compare **35** *versus* **34**; **33** *versus* **28**; **22** *versus* **16**). Introduction of a methyl group at the 6-position in both series giving compounds **28** and **33** was responsible for a marked decrease of potency on AMPARs compared to the unsubstituted compounds **34** and **35** (compare **28** *versus* **34** and **33** *versus* **35**) supporting the view that the absence of a substituent at this position should be preferred. On the contrary, with the dimeric compounds bearing an alkyl link at this key position, a substantial improvement of activity on AMPARs, up to more than 10,000 times (4 log units) compared to their corresponding monomers, was observed (compare **16** *versus* **34** and **22** *versus* **35**). This major enhancement led to the identification of one of the most potent AMPApams (compound **22**) ever described with an EC<sub>50</sub> value of 1.4 nM (pEC<sub>50</sub> value of -8.90).

We recently demonstrated that the Hill coefficient (HC), which is sometimes improperly referred to as the "slope" of the sigmoidal curve,<sup>38</sup> of the concentration-response curves obtained in our functional assay was a good surrogate to estimate the binding stoichiometry of AMPApams.<sup>26</sup> Therefore, calculation of the HC has been included in Table 2. It was noticed that compounds **16** and **22** were characterized by a HC closer to unity, a profile that we previously observed for compound **8**.<sup>26</sup> Such observations strongly suggest that the dimeric compounds have a different binding stoichiometry compared to their monomeric counterparts **28** and **33**. These data are consistent with the nature of these dimeric compounds establishing a bridge between two AMPAR subunits, forming a single binding pocket at this interface.

The observation that the interaction of 7-phenoxy-substituted BTDs with two distant AMPAR subunits led to a drastic enhancement of the activity<sup>26</sup> seems to be confirmed here with the

dimeric compounds. To our knowledge, the BTD-type AMPApam family shows an effect either on the deactivation or the desensitization process.<sup>2</sup> With the dimeric modulators we observe a “staple effect”, or at least a bridge effect, in which the dimeric compound acts by “sticking” the two LBD subunits together, leading to a locked position of the 2-fold symmetric GluA2 dimer and thus most probably inhibiting completely the desensitization phenomenon. This hypothesis is strengthened by studies on iGluRs involving rigid bridging through cysteine-cysteine interaction where the linking of the two different parts of the LBD with a similar bridge significantly affected desensitization.<sup>39-41</sup>

#### ***Co-crystallization of dimeric compound 16 with GluA2<sub>o</sub>-LBD shows 1:2 stoichiometry***

To establish the binding mode of **16** at AMPARs, we crystallized **16** in complex with GluA2<sub>o</sub>-LBD and L-glutamate. Diffraction data were collected to a high resolution of 1.4 Å (Table 3). The complex crystallized with two GluA2<sub>o</sub>-LBD molecules in the crystal asymmetric unit, forming a dimer (Figure 4A). Unambiguous electron density was observed for L-glutamate in both orthosteric binding sites and for one molecule of **16** at the dimer interface (Figure 4B). In the presence of **16**, L-glutamate induces a domain closure of 20.7° (chain A) and 21.7° (chain B) relative to the apo structure of GluA2<sub>o</sub>-LBD (pdb-code 1FTJ, chain A). These domain closures are similar to those observed with L-glutamate with no modulator bound.<sup>42</sup>

Compound **16** binds at GluA2 in a low energy conformation (2.8 kJ/mol above the global energy minimum). Therefore, introducing an ethylene bridge in **16** only gives rise to a minor conformational penalty. For the dimeric modulator **16** the potency at GluA2 was increased ~30,000 and ~13,000 times, respectively, compared to its monomeric parent compound **28** (6-

1  
2  
3 methyl) and the monomeric compound containing a 6-hydrogen (**34**) (Table 1). Similarly,  
4  
5 compound **22** was superior to its monomeric parent compound **33** (~34,000) and **35** containing  
6  
7 6-hydrogen (~7,000). The increase in potencies corresponds to a more favorable energy of 22-26  
8  
9 kJ/mol. It has previously been shown that the potency of a bivalent modulator was greater than  
10  
11 the sum of its fragments.<sup>27</sup> This could be due to a decreased loss of rotational and translational  
12  
13 entropy (from freezing of the overall molecular motion) in the dimeric compound resulting from  
14  
15 joining the fragments compared to the binding of two individual components of the monomer.  
16  
17 However, other aspects related to enthalpy might also be involved such as decreased rate of  
18  
19 dissociation of the dimer. The 6-hydrogen containing compounds **34** and **35** have a greater  
20  
21 potency than 6-methyl compounds **28** and **33** (~2 and 5 times, respectively). This is in agreement  
22  
23 with that **34** and **35** can bind in a similar manner in GluA2 as **16**, whereas a different binding  
24  
25 mode is required for **28** and **33** to avoid clash between the two methyl groups.  
26  
27  
28  
29  
30  
31  
32

33 Compound **16** binds to the allosteric binding site in the same region as other BTM modulators.  
34  
35 The binding mode of the dimeric modulator **16** is similar to that of the monomeric modulator **6**  
36  
37 (Figure 4C). However, a slight displacement of the BTM ring systems of ~0.5 Å was observed.  
38  
39 Previously, it was shown that introduction of a cyclopropyl group at the 4-*N* nitrogen in the  
40  
41 monomeric modulator (**6**) led to 10 times improved binding affinity compared to an ethyl group  
42  
43 (**5**).<sup>29</sup> This is in agreement with what we observed in the present study, namely a 10 times  
44  
45 greater potency of **22** (with cyclopropyl) compared to **16** (with methyl) (Table 2). Compound **16**  
46  
47 binds symmetrically in both the B/B' and C/C' subsites (Fig. 4C).  
48  
49  
50  
51

52 Similarly to **16** and **22**, compound **8** can be considered a dimeric modulator, but it is asymmetric.  
53  
54 However, the 3-methoxyphenoxy substituent of **8** occupies a different space than the  
55  
56  
57  
58  
59  
60

benzothiadiazine dioxide of **16**, with the benzene ring positioned perpendicular to the backbone of Met517 and Ser518.<sup>26</sup>

The following residues are within 4 Å of **16**: Lys514, Pro515, Phe516, Met517, Ser518, Ser750, Lys751, Gly752, Leu772 and Asn775 of both subunits comprising the GluA2<sub>o</sub>-LBD dimer (numbering with signal peptide). Of these residues, Lys514, Pro515, Ser518, Ser750, Leu772 and Asn775 are protruding into the modulator binding site (Figure 4B). Notably, Ser518 and Ser750 are present in two side-chain conformations in both subunits of which one conformation of Ser518 in both subunits are lining the ethylene bridge of **16**. Both conformations of Ser518 form water-mediated contacts to both conformations of Ser750 (Figure 4B). Compound **16** only forms two hydrogen bonds to the receptor subunits: a hydrogen bond is seen from both sulfonamide nitrogen atoms of **16** to the backbone oxygen atom of Pro515 in each subunit (Figure 4B). In addition, a water-mediated hydrogen bond is formed from an oxygen atom of each sulfonamide in **16** to the side chain of Asn775. Thus, the monomeric parts of **16** make polar contacts to the receptor subunits in a symmetrical manner.

## **Conclusions**

The aim of the present study was to develop dimeric compounds able to fit the allosteric binding sites located on both sides of the AMPAR dimer interface. The design of such molecules was motivated by the putative gain of activity resulting from a double occupancy of the binding site. Previous X-ray data obtained with “monomeric” BTD-type AMPApams clearly highlighted the close proximity of two molecules of such modulator on two close receptor subunits and that it

could be possible to design dimeric molecules interacting with both sides of the LBD dimer interface.

Molecular modeling was used to compute the virtual docking of a series of large dimeric molecules in the double-sided allosteric pocket. The best fits were obtained with dimeric compounds linked together by an ethylene bridge between their respective 6-positions. It should be noticed that there was a little difference in the predicted binding affinities between compounds differing by the nature of the substituent (methyl or cyclopropyl) introduced at the 4-position of the two BTB scaffolds.

According to these data, two dimeric molecules, compounds **16** and **22**, were selected for chemical synthesis. This was done following two different synthetic pathways. For the 4-methyl-substituted compound **16**, a convergent pathway was developed in which the 1,2,4-benzothiadiazine 1,1-dioxide ring was first built and for which the cross linkage took place in the last steps. For the 4-cyclopropyl-substituted compound **22**, the cross linking step was performed much earlier in the synthesis route and the ring closure of the heterocycle was built in the final steps.

The pharmacological evaluation of the target compounds and their corresponding constitutive monomers was performed on HEK293 cells expressing the GluA2<sub>o</sub>(Q) receptor and the variations of cytoplasmic calcium content were followed with a fluorescent probe. The AMPA activity of dimeric compound **22** was found to be approximately 10 times higher than dimeric compound **16**, an observation that differ only slightly from the docking results. For the whole series of tested compounds, the cyclopropyl group was always found to be the best choice of alkyl substituent at the 4-position of the BTB ring. Interestingly, both dimeric

1  
2  
3 molecules **16** and **22** showed about 10,000 times lower EC<sub>50</sub> values than their corresponding  
4 unsubstituted BTM monomers (compounds **34** and **35**). To the best of our knowledge, compound  
5  
6 **22**, with an EC<sub>50</sub> value of 1.4 nM, may be considered as one of the most potent AMPA-pam ever  
7 described in the literature, expressing a potency in the same order of magnitude as the recently  
8 described compound **8**.<sup>26</sup> Ultimately, the co-crystallization of dimeric compound **16** with the  
9 GluA2<sub>o</sub>-LBD clearly demonstrated that the two allosteric binding sites located at the LBD dimer  
10 interface were able to host the dimeric compound occupying the position of two separated  
11 monomers.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## 26 **Experimental section**

27  
28  
29 **General procedures.** Melting points were determined on a Büchi Tottoli capillary apparatus and  
30 are uncorrected. The <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance (500 MHz for  
31 <sup>1</sup>H; 125 MHz for <sup>13</sup>C) instrument using deuterated dimethyl sulfoxide (DMSO-*d*<sub>6</sub>) as the solvent  
32 with tetramethylsilane (TMS) as an internal standard; chemical shifts are reported in δ values  
33 (ppm) relative to that of internal TMS. The abbreviations s = singlet, d = doublet, t = triplet, q =  
34 quadruplet, m = multiplet, dd = doublet of doublet, qd = quadruplet of doublet, dt = doublet of  
35 triplet, tt = triplet of triplet and bs = broad singlet are used throughout. Elemental analyses (C, H,  
36 N, S) were realized on a Thermo Scientific Flash EA 1112 elemental analyzer and were within ±  
37 0.4% of the theoretical values for carbon, hydrogen and nitrogen. This analytical method  
38 certified a purity of ≥ 95% for each tested compound. All reactions were routinely checked by  
39 TLC on silica gel Merck 60 F254.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 **4-Bromo-2-(methylamino)benzenesulfonamide (11).** 4-Bromo-2-fluorobenzenesulfonamide  
56  
57  
58  
59  
60



(**10**) (4 g, 15.7 mmol) was dissolved in a 1:3 mixture of 1,4-dioxane and methylamine solution 40% in water (20 mL). The solution was heated in a microwave oven at 135°C for 25 min. After cooling, the solvent was removed by distillation under reduced pressure. The pink solid was suspended in water, collected by filtration and dried in a vacuum desiccator (yield: 96%); m.p.: 171-173°C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 7.51 (d, *J*=8.4 Hz, 1H, 6-*H*), 7.38 (s, 2H, SO<sub>2</sub>NH<sub>2</sub>), 6.87 (d, *J* = 1.8 Hz, 1H, 3-*H*), 6.82 (dd, *J* = 8.4 Hz/1.9 Hz, 1H, 5-*H*), 6.01 (q, *J* = 4.5 Hz, 1H, NH), 2.83 (d, *J* = 4.9 Hz, 3H, NHCH<sub>3</sub>) ; <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 146.7 (C-1), 130.0 (C-6), 127.2 (C-4), 124.1 (C-2), 117.0 (C-5), 113.3 (C-3), 30.0 (NCH<sub>3</sub>).

**2-(Methylamino)-4-vinylbenzenesulfonamide (12).** To a solution of 4-bromo-2-(methylamino)benzenesulfonamide (**11**) (1.9 g, 7.17 mmol) in 1,4-dioxane (14 mL), potassium vinyltrifluoroborate (1.15 g, 8.6 mmol, 1.2 eq.) was added. Once the salt was completely solubilized, an aqueous solution of NaOH 10% (6.3 mL) was added, followed by Pd(OAc)<sub>2</sub> (4.3 mg, 0.27 mol%). This mixture was heated to reflux for 24 h. Once returned to room temperature, the crude black suspension was filtered. The aqueous filtrate was then extracted with ethyl acetate (3 x 25 mL). The organic layers were combined, washed with brine (15 mL) and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure and the oily residue was recrystallized in a mixture of methanol/water 1:2 (yield: 33%); m.p.: 128-131°C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 7.57 (d, *J* = 8.2 Hz, 1H, 6-*H*), 7.26 (s, 2H, SO<sub>2</sub>NH<sub>2</sub>), 6.80 (d, *J* = 8.3 Hz, 1H, 5-*H*), 6.76 (s, 1H, 3-*H*), 6.72 (dd, *J* = 17.7, 10.9 Hz, 1H, CH<sub>2</sub>CH), 5.92 (d, *J* = 17.6 Hz, 1H, Z-CH<sub>2</sub>CH), 5.87 (q, *J* = 4.9 Hz, 1H, NHCH<sub>3</sub>), 5.35 (d, *J* = 10.9 Hz, 1H, E-CH<sub>2</sub>CH), 2.86 (d, *J* = 4.9 Hz, 3H, NCH<sub>3</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 145.9 (C-1), 141.8 (C-4), 136.4 (CH), 128.5 (C-6), 124.0 (C-2), 116.4 (CH<sub>2</sub>), 111.9 (C-5), 109.0 (C-3), 29.6 (NCH<sub>3</sub>).

**4-Methyl-6-vinyl-4*H*-1,2,4-benzothiadiazine 1,1-dioxide (13).** 2-(Methylamino)-4-vinylbenzenesulfonamide (**12**) (1.13 g, 5.3 mmol) was heated under stirring in triethyl orthoformate (5 mL) at 135°C for 4 hours. The resulting suspension was cooled on an ice bath and the solid product was collected by filtration, washed with ether and dried (yield: 81%); m.p.: >300°C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.08 (s, 1H, 3-*H*), 7.85 (d, *J* = 8.2 Hz, 1H, 8-*H*), 7.70 (dd, *J* = 8.3, 1.4 Hz, 1H, 7-*H*), 7.52 (d, *J* = 1.4 Hz, 1H, 5-*H*), 6.88 (dd, *J* = 17.7, 11.0 Hz, 1H CH<sub>2</sub>CH), 6.14 (d, *J* = 17.6 Hz, 1H, *Z*-CH<sub>2</sub>CH), 5.53 (d, *J* = 10.9 Hz, 1H, *E*-CH<sub>2</sub>CH), 3.65 (s, 3H, NCH<sub>3</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 151.3 (C-3), 141.7 (C-6), 136.2 (C-4a), 135.1 (CH), 124.4 (C-8), 123.9 (C-7), 121.6 (C-8a), 118.7 (CH<sub>2</sub>), 114.3 (C-5), 38.2 (NCH<sub>3</sub>).

**4-Methyl-6-vinyl-3,4-dihydro-2*H*-1,2,4-benzothiadiazine 1,1-dioxide (14).** 4-Methyl-6-vinyl-4*H*-1,2,4-benzothiadiazine 1,1-dioxide (**13**) (0.4 g, 1.83 mmol) was stirred in suspension in isopropanol (10 mL) at 60°C. NaBH<sub>4</sub> (0.2 g, 3 eq.) was added and the mixture was stirred for 15 min. The solvent was removed by distillation under reduced pressure and the crude product was taken in water and the suspension was adjusted to acidic pH by means of 6N HCl. The aqueous suspension was then extracted with methylene chloride (3 x 30 mL). The combined organic layers were washed with brine and dried over MgSO<sub>4</sub>. The filtrate was evaporated to dryness and the resulting solid residue was suspended in water, collected by filtration, washed with water and dried (yield: 61%); m.p.: > 300°C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.03 (t, *J* = 7.9 Hz, 1H, NH), 7.49 (d, *J* = 8.1 Hz, 1H, 8-*H*), 6.95 (d, *J* = 8.1 Hz, 1H, 7-*H*), 6.88 (d, *J* = 1.4 Hz, 1H, 5-*H*), 6.72 (dd, *J* = 17.6, 10.9 Hz, 1H, CH<sub>2</sub>CH), 5.95 (dd, *J* = 17.6, 0.8 Hz, 1H, *Z*-CH<sub>2</sub>CH), 5.38 (d, *J* = 11.0 Hz, 1H, *E*-CH<sub>2</sub>CH), 4.65 (d, *J* = 8.1 Hz, 2H, CH<sub>2</sub>), 2.97 (s, 3H, NCH<sub>3</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 144.4 (C-6), 141.6 (C-4a), 136.2 (CH<sub>2</sub>CH), 124.4 (C-8), 122.0 (C-8a), 116.5 (CH<sub>2</sub>CH), 113.6 (C-7), 111.7 (C-5), 62.2 (C-3), 35.9 (NCH<sub>3</sub>).

**(E)-6,6'-(Ethene-1,2-diyl)bis(4-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (15)).** 4-Methyl-6-vinyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (**14**) (0.2 g, 0.89 mmol) was solubilized in methylene chloride (3 mL) and supplemented with Hoveyda-Grubbs II catalyst (0.01 mol%) under nitrogen, and the mixture was heated to reflux. Every 30 min, the nitrogen was fluxed and replaced with fresh volume. After 4 hours, the reaction mixture was cooled to room temperature and the solid was collected by filtration, washed with ether and dried (yield: 65%); m.p.: 331°C (decomposition); <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.06 (t, *J* = 7.9 Hz, 1H, NH), 7.54 (d, *J* = 8.1 Hz, 1H, 8-*H*), 7.37 (s, 1H, CH), 7.10 (dd, *J* = 8.2, 1.6 Hz, 1H, 7-*H*), 7.05 (d, *J* = 1.5 Hz, 1H, 5-*H*), 4.68 (d, *J* = 7.6 Hz, 2H, CH<sub>2</sub>), 3.01 (s, 3H, NCH<sub>3</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 144.3 (C-6), 141.2 (C-4a), 130.0 (CH linker), 124.5 (C-8), 121.8 (C-8a), 114.3 (C-7), 112.2 (C-5), 62.3 (C-3), 36.2 (NCH<sub>3</sub>).

**6,6'-(Ethane-1,2-diyl)bis(4-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide) (16).** (E)-6,6'-(Ethene-1,2-diyl)bis(4-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (**15**) (0.13 g, 0.31 mmol) was dissolved in DMF (5 mL) and was supplemented with 10% palladium on charcoal (13 mg). The resulting suspension was placed under 12 bars of H<sub>2</sub> for one hour. The solvent was removed by distillation under reduced pressure and the residue was recrystallized in methanol, collected by filtration and dried (yield: 25%); m.p.: 313°C (decomposition); <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 7.91 (s, 1H, NH), 7.42 (d, *J* = 7.4 Hz, 1H, 8-*H*), 6.71 (s, 1H, 5-*H*), 6.70 (dd, *J* = 7.1 Hz / 1.2 Hz, 1H, 7-*H*), 4.62 (s, 2H, CH<sub>2</sub>), 2.91 (s, 3H, NCH<sub>3</sub>), 2.86 (s, 2H, CH<sub>2</sub> (linker)); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 146.9 (C-6), 144.0 (C-4a), 124.0 (C-8), 120.6 (C-8a), 116.8 (C-7), 113.4 (C-5), 62.4 (C-3), 36.7 (CH<sub>2</sub> linker), 36.2 (NCH<sub>3</sub>); Anal. (C<sub>18</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub>S<sub>2</sub>): calculated: N 13.26%, C 51.17%, H 5.25%, S 15.18%; found: N 13.22%, C 51.29%, H 5.29%, S 14.71%.

**4-Bromo-2-(cyclopropylamino)benzenesulfonamide (17).** 4-Bromo-2-

fluorobenzenesulfonamide (**10**) (4.0 g, 15.7 mmol) was dissolved in a 1:1 mixture of 1,4-dioxane and cyclopropylamine (20 mL). The solution was heated in a microwave oven to 135°C for 25 min. After cooling, the solvent was removed by distillation under reduced pressure. The solid residue was recrystallized from methanol/water 1:2, collected by filtration, washed with water and dried in a vacuum desiccator (yield: 75%); m.p.: 201-204°C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 7.52 (d, *J* = 8.4 Hz, 1H, 6-*H*), 7.43 (bs, 2H, SO<sub>2</sub>NH<sub>2</sub>), 7.25 (d, *J* = 1.9 Hz, 1H, 3-*H*), 6.90 (dd, *J* = 8.4, 1.9 Hz, 1H, 5-*H*), 6.21 (d, *J* = 1.8 Hz, 1H, NH), 2.50 (m, 1H, CH(CH<sub>2</sub>)<sub>2</sub>), 0.87 – 0.76 (m, 2H, CH(CH<sub>2</sub>)<sub>2</sub>), 0.56 – 0.49 (m, 2H, CH(CH<sub>2</sub>)<sub>2</sub>). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 146.6 (C-1), 129.9 (C-6), 126.8 (C-4), 124.4 (C-2), 118.0 (C-5), 114.9 (C-3), 24.2 (NCH<sub>3</sub>), 7.1 (CH(CH<sub>2</sub>)<sub>2</sub>).

**2-(Cyclopropylamino)-4-vinylbenzenesulfonamide (18).** The title compound was obtained according to the procedure described for compound **12** starting from compound **17** (yield: 86%); m.p.: 155-161°C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 7.61 – 7.51 (m, 1H, 6-*H*), 7.31 (s, 2H, SO<sub>2</sub>NH<sub>2</sub>), 7.15 (d, *J* = 1.6 Hz, 1H, 3-*H*), 6.87 (dd, *J* = 8.2, 1.6 Hz, 1H, 5-*H*), 6.74 (dd, *J* = 17.6, 10.9 Hz, 1H, CHCH<sub>2</sub>), 6.11 (s, 1H, NH), 5.90 (d, *J* = 1.7 Hz, 1H, Z-CHCH<sub>2</sub>), 5.37 (d, *J* = 17.5 Hz, 1H, E-CHCH<sub>2</sub>), 2.50 (m, 1H, CH(CH<sub>2</sub>)<sub>2</sub>), 0.88 – 0.72 (m, 2H, CH(CH<sub>2</sub>)<sub>2</sub>), 0.57 – 0.43 (m, 2H, CH(CH<sub>2</sub>)<sub>2</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 146.0 (C-4), 141.0 (C-1), 136.3 (CHCH<sub>2</sub>), 128.0 (C-6), 124.0 (C-2), 116.4 (CH<sub>2</sub>), 113.0 (C-5), 110.7 (C-3), 24.5 (CH(CH<sub>2</sub>)<sub>2</sub>), 7.2 (CH(CH<sub>2</sub>)<sub>2</sub>).

**(E)-4,4'-(Ethene-1,2-diyl)bis(2-(cyclopropylamino)benzenesulfonamide) (19).** The title compound was obtained according to the procedure described for compound **15** starting from compound **18** (yield: 89%); m.p.: 247°C (decomposition); <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ

7.61 (d,  $J = 8.3$  Hz, 1H, 6-*H*), 7.37 – 7.28 (m, 3H, SO<sub>2</sub>NH<sub>2</sub> and 3-*H*), 7.09 (dd,  $J = 8.4$ , 1.5 Hz, 1H, 5-*H*), 6.16 – 6.11 (m, 1H, NH), 2.56 (tt,  $J = 6.4$ , 3.3 Hz, 1H, CH(CH<sub>2</sub>)<sub>2</sub>), 0.86 (m,  $J = 6.6$ , 3.3 Hz, 2H, CH(CH<sub>2</sub>)<sub>2</sub>), 0.55 (m,  $J = 4.4$  Hz, 2H, CH(CH<sub>2</sub>)<sub>2</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  145.6 (C-4), 141.1 (C-1) 130.0 (C-6), 128.5 (CH linker), 124.1 (C-2), 113.3 (C-5), 111.6 (C-3), 24.6 (NCH), 7.4 (CH(CH<sub>2</sub>)<sub>2</sub>).

**4,4'-(Ethane-1,2-diyl)bis(2-(cyclopropylamino)benzenesulfonamide) (20).** The title compound was obtained according to the procedure described for compound **16** starting from compound **19** (yield: 90%); m.p.: 220-222°C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  7.50 (d,  $J = 8.1$  Hz, 1H, 6-*H*), 7.23 (s, 2H, SO<sub>2</sub>NH<sub>2</sub>), 6.94 (d,  $J = 1.6$  Hz, 1H, 3-*H*), 6.62 (dd,  $J = 8.1$ , 1.7 Hz, 1H, 5-*H*), 6.05 (d,  $J = 1.6$  Hz, 1H, NH), 2.90 (s, 2H, CH<sub>2</sub>), 2.43 – 2.37 (m, 1H, CH(CH<sub>2</sub>)<sub>2</sub>), 0.76 (dt,  $J = 6.6$ , 3.3 Hz, 2H, CH(CH<sub>2</sub>)<sub>2</sub>), 0.50 – 0.41 (m, 2H, CH(CH<sub>2</sub>)<sub>2</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  146.8 (C-4), 145.5 (C-1), 128.0 (C-6) 123.0 (C-2), 115.9 (C-5), 112.6 (C-3), 36.4 (CH<sub>2</sub> linker), 24.5 (NCH), 7.3 (CH(CH<sub>2</sub>)<sub>2</sub>).

**6,6'-(Ethane-1,2-diyl)bis(4-cyclopropyl-4*H*-1,2,4-benzothiadiazine 1,1-dioxide) (21).** The title compound was obtained according to the procedure described for compound **13** starting from compound **20** (yield: 87%); m.p.: 298°C (decomposition); <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  8.09 (s, 1H, 3-*H*), 7.81 (d,  $J = 8.1$  Hz, 1H, 8-*H*), 7.53 (s, 1H, 5-*H*), 7.47 (d,  $J = 8.1$  Hz, 1H, 7-*H*), 3.26 (m,  $J = 7.2$ , 3.9 Hz, 1H, CH(CH<sub>2</sub>)<sub>2</sub>), 3.15 (s, 2H, CH<sub>2</sub> linker), 1.09 (t,  $J = 6.6$  Hz, 2H CH(CH<sub>2</sub>)<sub>2</sub>), 0.93 – 0.84 (m, 2H, CH(CH<sub>2</sub>)<sub>2</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  151.4 (C-3), 146.6 (C-6), 136.3 (C-4a), 127.2 (C-8), 124.1 (C-7), 120.3 (C-8a), 116.3 (C-5), 36.3 (CH<sub>2</sub> linker), 32.1 (NCH), 7.3 (CH(CH<sub>2</sub>)<sub>2</sub>).

**6,6'-(Ethane-1,2-diyl)bis(4-cyclopropyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide) (22).** The title compound was obtained according to the procedure described for compound **14** starting from compound **21** suspended in isopropanol and using DMF drop by drop until the reactant was in solution before the addition of NaBH<sub>4</sub> (yield: 82%); m.p.: 290°C (decomposition); <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 7.78 (t, *J* = 7.9 Hz, 1H, *NH*), 7.43 (d, *J* = 8.0 Hz, 1H, 8-*H*), 7.02 (d, *J* = 1.5 Hz, 1H, 5-*H*), 6.75 (dd, *J* = 8.1, 1.5 Hz, 1H, 7-*H*), 4.61 (d, *J* = 7.7 Hz, 2H, 3-*H*), 2.92 (s, 2H, CH<sub>2</sub> linker), 2.41 (m, 1H, CH(CH<sub>2</sub>)<sub>2</sub>), 0.90 – 0.84 (m, 2H, CH(CH<sub>2</sub>)<sub>2</sub>), 0.58 (m, 2H, CH(CH<sub>2</sub>)<sub>2</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 146.1 (C-6), 143.9 (C-4a), 124.2 (C-8), 121.2 (C-8a), 117.8 (C-7), 114.2 (C-5), 61.0 (C-3), 36.5 (CH<sub>2</sub> linker), 29.6 (NCH), 8.4 (CH(CH<sub>2</sub>)<sub>2</sub>). Anal. (C<sub>22</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>S<sub>2</sub>): calculated: N 11.80% C 55.68% H 5.52% S 13.51%; found: N 11.77% C 55.88% H 5.67% S 13.05%.

**2-Amino-4-methylbenzenesulfonamide (25).** A solution of *m*-toluidine (**23**) (10 g, 93.3 mmol) in nitromethane (40 mL) was added to a stirred, ice-cooled solution of chlorosulfonyl isocyanate (9 mL) in nitromethane (25 mL) during 5 minutes. This addition resulted in a suspension. Aluminium chloride (14.0 g, 105 mmol) was added at once, resulting in a clear solution. The reaction mixture was then refluxed for 30 minutes, cooled, and poured into ice-water. The precipitated solid was collected by filtration and washed with water. The precipitate was suspended in water and then extracted three times with ethyl acetate. The combined organic layers were dried over MgSO<sub>4</sub> and filtered. The filtrate was concentrated to dryness under reduced pressure. The residue was taken in water (100 mL) and the mixture was adjusted to pH 12 with NaOH 10% w/w in water, treated with charcoal and filtered. The filtrate was then acidified by addition of 12N HCl, and the solid that precipitated was collected by filtration. This solid consisted in the mixture of the two isomers (**24a** and **24b**). This solid was dispersed in 50%

w/w sulfuric acid in water and refluxed during 6 hours. After being cooled, the mixture was filtered and afforded a solid (mainly unchanged **24a**) and a filtrate containing compound **25**. After neutralizing the filtrate with NaOH 40% w/w in water, the solvent was evaporated under reduced pressure. The residue was suspended in hot ethanol (200 mL) and filtered. The resulting filtrate was concentrated to dryness under reduced pressure and the residue of the title compound was recrystallized in methanol:water 1:2 (yield: 19%); m.p.: 121-122°C (lit. 124-126°C<sup>43</sup>).

**6-Methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide (26).** The title compound was obtained according to the procedure described for compound **13** starting from compound **25** (yield: 76%); m.p.: 186-195°C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) δ 12.17 (s, 1H, *NH*), 7.94 (s, 1H, 3-*H*), 7.69 (d, 1H, 8-*H*), 7.58 (s, 1H, 5-*H*), 7.25 (d, 1H, 7-*H*), 2.39 (s, 3H, 6-*CH*<sub>3</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 147.5 (C-3), 143.5 (C-6), 134.6 (C4a), 127.7 (C-8a), 123.6 (C-8), 120.1 (C-7), 117.0 (C-5), 21.1 (CH<sub>3</sub>).

**4,6-Dimethyl-4H-1,2,4-benzothiadiazine 1,1-dioxide (27).** The mixture of 6-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide (**26**) (1 g, 4.62 mmol), potassium carbonate (2 g), and methyl iodide (1.7 mL) in acetonitrile (30 mL) was heated at 60°C for 3 h. The solvent was removed by distillation under reduced pressure and the residue was suspended in water (40 mL). The resulting insoluble material was collected by filtration, washed with water, dried and recrystallized in ethyl acetate (yield: 75%); m.p.: 269-272°C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) 8.04 (s, 1H, 3-*H*), 7.76 (d, 1H, 8-*H*), 7.37 (d, 1H, 7-*H*), 7.32 (s, 1H, 5-*H*), 3.59 (s, 3H, NCH<sub>3</sub>), 2.44 (s, 3H, 6-CH<sub>3</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 151.1 (C-3), 143.8 (C-6), 135.8 (C-4a), 127.7 (C-7), 124.0 (C-8), 120.2 (C-8a), 116.4 (C-5), 38.0 (NCH<sub>3</sub>), 21.4 (6-CH<sub>3</sub>).

**4,6-Dimethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (28).** The title compound was obtained according to the procedure described for compound **14** starting from compound **27** (yield: 75%); m.p.: 141-142°C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) δ 7.95 (t, 1H, NH) 7.40 (d, 1H, 8-H), 6.66 (s, 1H, 5-H), 6.62 (d, 1H, 7-H), 4.63 (d, 2H, 3-H<sub>2</sub>), 2.92 (s, 3H, NCH<sub>3</sub>), 2.29 (s, 3H, 6-CH<sub>3</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 144.0 (C-6), 143.3 (C-4a), 124.0 (C-8), 120.3 (C-8a), 117.3 (C-7), 113.8 (C-5), 62.3 (C-3), 36.1 (NCH<sub>3</sub>), 21.6 (6-CH<sub>3</sub>). Anal. (C<sub>9</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S): calculated: N 13.20%, C 50.92%, H 5.70% S 15.10%; found: N 13.14%, C 50.61%, H 5.50% S 15.53%.

**2-Fluoro-4-methylbenzenesulfonamide (30).** A portion of glacial acetic acid (160 mL) was saturated for 30 min with gaseous sulfur dioxide. To the resulting solution, cooled on an ice bath, was added under stirring an aqueous solution of CuCl<sub>2</sub> (7 g in 20 mL) (suspension A). 2-Fluoro-4-methylaniline (**29**) (15 g, 87 mmol) was dissolved in a mixture of glacial acetic acid (160 mL) and 16N HCl (40 mL). To the resulting solution, cooled in an ice-salt bath (−5 °C), was added dropwise under stirring an aqueous solution of NaNO<sub>2</sub> (8 g in 20 mL, 116 mmol). At the end of the addition, the resulting solution was slowly mixed with suspension A. After being stirred for 15 min, the suspension was poured onto ice (400 g). The resulting precipitate was collected by filtration, washed with water, and immediately dissolved in 1,4-dioxane (150 mL). The solution obtained was added gradually, under stirring, to a concentrated ammonium hydroxide solution (300 mL) previously cooled on an ice bath. After the resulting solution was stirred for 30 min, the organic solvent and part of the ammonia were removed by evaporation under reduced pressure. The aqueous solution/suspension obtained was adjusted to neutral pH by adding 6N HCl. The precipitate formed was collected by filtration, washed with water and dried (yield: 37%); m.p.: 136-137°C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 7.66 (t, *J* = 7.9 Hz, 1H, 8-*H*), 7.59 (d,



$J = 4.7$  Hz, 2H,  $\text{SO}_2\text{NH}_2$ ), 7.26 (d,  $J = 11.3$  Hz, 1H, 7-*H*), 7.17 (t,  $J = 6.4$  Hz, 1H, 3-*H*), 2.38 (d,  $J = 4.0$  Hz, 3H,  $\text{CH}_3$ );  $^{13}\text{C}$  NMR (125 MHz,  $\text{DMSO}-d_6$ )  $\delta$  158.9 - 156.9 (d,  $J = 252.3$  Hz, C-2), 145.5 (C-1), 128.8 - 128.7 (d,  $J = 14.4$  Hz, C-6), 128.1 (C-4), 124.9 (C-5), 117.3 - 117.1 (d, 20.8 Hz, C-3), 20.8 ( $\text{CH}_3$ ).

**2-(Cyclopropylamino)-4-methylbenzenesulfonamide (31).** 2-Fluoro-4-methylbenzenesulfonamide (**30**) (5 g, 21 mmol) was introduced into a hermetically closed vessel containing a mixture of 1,4-dioxane (70 mL) and cyclopropylamine (3.5 mL, 50 mmol). The closed vessel was placed in an oven at 100 °C for 240 h. After this time period, the solvent and the reagent were removed by distillation under reduced pressure. The residue was taken up in methanol (20 mL), and the insoluble material, which contained the title product, was collected by filtration, washed with methanol, and dried. This compound was used in the next step without further purification (yield: 35%);  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO}-d_6$ )  $\delta$  7.48 (d,  $J = 7.9$  Hz, 1H, 6-*H*), 7.23 (s, 2H,  $\text{SO}_2\text{NH}_2$ ), 6.94 (s, 1H, 3-*H*), 6.58 – 6.49 (m, 1H, 5-*H*), 6.06 (s, 1H, *NH*), 2.45 (dp,  $J = 9.7, 3.7, 3.2$  Hz, 1H,  $\text{CH}(\text{CH}_2)_2$ ), 2.29 (s, 3H,  $\text{CH}_3$ ), 0.85 – 0.71 (m, 2H,  $\text{CH}(\text{CH}_2)_2$ ), 0.50 (p,  $J = 4.3$  Hz, 2H,  $\text{CH}(\text{CH}_2)_2$ );  $^{13}\text{C}$  NMR (125 MHz,  $\text{DMSO}-d_6$ )  $\delta$  145.4 (C-4), 143.2 (C-1), 128.1 (C-6), 122.6 (C-2), 116.4 (C-5), 113.0 (C-3), 24.5 ( $\text{CH}(\text{CH}_2)_2$ ), 21.5 ( $\text{CH}_3$ ), 7.3 ( $\text{CH}(\text{CH}_2)_2$ ).

**4-Cyclopropyl-6-methyl-4*H*-1,2,4-benzothiadiazine 1,1-dioxide (32).** The title compound was obtained according to the procedure described for compound **13** starting from compound **31** (yield: 35%); m.p.: 224-226°C;  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO}-d_6$ )  $\delta$  8.12 (s, 1H, 3-*H*), 7.77 (d,  $J = 7.9$  Hz, 1H, 8-*H*), 7.64 (s, 1H, 5-*H*), 7.39 (d,  $J = 8.4$  Hz, 1H, 7-*H*), 3.34 (bs with water, 1H, *NCH*), 2.48 (s, 3H,  $\text{CH}_3$ ), 1.30 – 1.08 (m, 2H,  $\text{CH}(\text{CH}_2)_2$ ), 1.00 (dt,  $J = 6.9, 4.9$  Hz, 2H,

CH(CH<sub>2</sub>)<sub>2</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 151.4 (C-3), 143.7 (C-6), 136.5 (C-4a), 127.6 (C-7), 124.0 (C-8), 119.8 (C-8a), 116.5 (C-5), 32.1 (CH<sub>3</sub>), 21.6 (NCH), 7.3 (CH(CH<sub>2</sub>)<sub>2</sub>).

**4-Cyclopropyl-6-methyl-3,4-dihydro-2*H*-1,2,4-benzothiadiazine 1,1-dioxide (33).** The title compound was obtained according to the procedure described for compound **14** starting from compound **32** (yield: 75%); m.p.: 157-158°C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 7.81 (s, 1H, *NH*), 7.45 – 7.38 (d, *J* = 8.0 Hz, 1H, 8-*H*), 7.08 (s, 1H, 5-*H*), 6.70 (d, *J* = 8.0 Hz, 1H, 7-*H*), 4.63 (d, *J* = 4.9 Hz, 2H, CH<sub>2</sub>), 2.32 (d, *J* = 5.1 Hz, 3H, CH<sub>3</sub>), 0.92 (qd, *J* = 6.5, 4.2 Hz, 2H, CH(CH<sub>2</sub>)<sub>2</sub>), 0.65 (q, *J* = 4.1, 2.8 Hz, 2H, CH(CH<sub>2</sub>)<sub>2</sub>); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 144.1 (C-6), 142.9 (C-4a), 124.2 (C-8), 120.8 (C-8a), 118.3 (C-7), 114.5 (C-5), 61.1 (C-3), 29.6 (CH<sub>3</sub>), 21.7 (NCH), 8.4(CH(CH<sub>2</sub>)<sub>2</sub>). Anal. (C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S) calculated: N 11.76%, C 55.44%, H 5.92%, S 13.45%; found: N 12.10%, C 55.78%, H 5.99%, S 13.60%.

**Fluorescent-based calcium assay on GluA2<sub>o</sub>(Q) cells.** The pharmacological evaluation of the target molecules was performed as described previously.<sup>26</sup> Briefly, HEK293 cells stably expressing AMPA channel GluA2<sub>o</sub>(Q) were routinely grown in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin and streptomycin (5000 U/mL), 1% L-glutamine (200 mM) and Geneticin (G418 – 600 mg/mL). The measurement of the fluorescence intensity was carried out using fluorescent microplate reader Fluoroskan Ascent FT equipped with two dispensers (Thermo Electron Corporation, Finland). After trypsinization, the cells were washed twice using Hanks balanced salt solution (HBS, 120 mM NaCl, 2 mM KCl, 2 mM CaCl<sub>2</sub>, 2 mM MgCl<sub>2</sub>, 10 mM HEPES, pH 7.4) and incubated for 1 h with fluorescent dye Fluo-4/AM (5 μg/mL; Molecular Probes, Invitrogen, Merelbeke

Belgium). The cells were rinsed twice with HBS, and 100  $\mu$ L of the resulting cell suspension in HBS buffer was introduced into each well of a 96-well plate (density of 150 000 cells/well). The evaluated compounds were applied at various concentrations (from  $10^{-11}$  M to  $3 \times 10^{-3}$  M, with maximal DMSO concentration = 1%). After shaking the plate 30 s at 1200 rpm, the emission was read at 538 nm after an excitation at 485 nm during 500 ms per measures. Measurement of a vehicle control was followed by injection of a 10 mM L-glutamate solution (10  $\mu$ L), a fluorescence measurement (2 min), 15 s of shaking at 1200 rpm and a final fluorescence measurement (5 min). The results are expressed as the  $EC_{50}$  value, which is the concentration required to reach half of the maximal intensity, and are calculated by nonlinear regression analysis (GraphPad Prism software) from at least three independent concentration-response curves made in triplicate.

**Molecular modeling.** The co-crystal structure of monomer **6** with the GluA2<sub>o</sub>-LBD-L504Y-N775S (pdb-code 4N07) was used in the docking study. The target protein was prepared with Discovery Studio 4.0 while the docking procedure was carried out with the automated GOLD 5.3.0 program.<sup>44</sup> The binding site was defined as a 10 Å sphere starting from the two monomers **6** in the crystal structure, allowing the incorporation of both monomers as well as the amino acids interacting with them. Potential dimeric compounds were sketched with ChemDraw (Perkin Elmer Informatics) and prepared for docking with Discovery Studio 4.0 (Accelrys Inc, San Diego, California, USA). For each ligand, the number of genetic algorithm (GA) run was set at 100. The default ChemPLP score function was used and the search efficiency was fixed at 200%. For the output, we asked GOLD to keep the twenty best solutions for each ligand. From these solutions, clusters based on the orientation adopted by the docking poses were identified. From the cluster having the highest occurrence, we kept the best representative (higher PLP

fitness score). This representative was then used for the minimization *in situ* and free binding energy calculation. The *in situ* minimization, free binding energy calculations and interactions visualization were performed with Discovery Studio (DS) 4.0 (Accelrys Inc, San Diego, California, USA). The *in situ* minimization and free binding energy calculation were launched in the same DS protocol. In this protocol, the ligand conformational entropy<sup>45,46</sup> was also considered (conformers generated with the BEST algorithm) and the Generalized Born with Molecular Volume (GBMV) was used as implicit solvent model.


### **Crystallography**

GluA2<sub>o</sub>-LBD was expressed and purified as previously described.<sup>47</sup> A suspension of **16** in buffer with glutamate and 10% DMSO (5 mM L-glutamate, 20 mM **16**, 10 mM HEPES (pH 7.0), 20 mM NaCl, 1 mM EDTA, 10% DMSO) was mixed using shaking in the cold room overnight. Then to the GluA2<sub>o</sub>-LBD solution (in 10 mM HEPES (pH 7.0), 20 mM NaCl, 1 mM EDTA) was added **16** suspension to a resulting concentration of 5 mg/mL protein and 7 mM **16** suspension. The protein-ligand suspension was left at 6°C for 4 days with periodically shaking. The hanging drop vapor diffusion method was used for crystallization of the complex at 6 °C. The drops consisted of 1 µL protein-ligand solution and 1 µL reservoir solution. The reservoir volume was 0.5 mL. The crystal used for data collection was obtained using reservoir solution consisting of 15% PEG4000, 0.3 M ammonium sulfate, 0.1 M phosphate-citrate buffer pH 4.5. The crystal was cryo-protected using reservoir solution containing 20% glycerol before flash-cooling in liquid nitrogen.


X-ray diffraction data were collected at BioMAX, MAX IV, Lund, Sweden to a resolution of 1.4 Å. The data were processed with XDS<sup>48</sup> and scaled using SCALA<sup>49</sup> in CCP4<sup>50</sup>. The structure

was solved with molecular replacement using PHASER<sup>51</sup> in CCP4, with the structure of GluA2<sub>o</sub>-L504Y-N775S-LBD in complex with glutamate and BPAM344 as search model (pdb-code 4N07; chain A). The structure was built with AUTOBUILD<sup>52</sup> in PHENIX<sup>53</sup>. The program MAESTRO [version 10.1.013, Schrödinger, LLC, New York, NY, 2015] was used to generate coordinate file for compound **16**. The energy minimization and conformational search were calculated in water. The parameter file of **16** was obtained using eLBOW<sup>54</sup>, keeping the geometry obtained from MAESTRO. The structure was manually adjusted in COOT<sup>55</sup> and refined in PHENIX with individual isotropic B-factors in the initial refinements and anisotropic B-factors at the final refinements, as well as riding H atoms. The structure validation was done using tools in COOT, MolProbity<sup>56</sup> in PHENIX and the wwPDB Validation Service. The LBD domain closure induced by **16** was calculated using the DynDom server<sup>57</sup> relative to the apo structure of GluA2<sub>o</sub>-LBD (pdb-code 1FTO, chain A). Figure 4 was made in PyMOL [version 2.0.3, The PyMOL Molecular Graphics Systems, V.S., LLC].


Figures



**Figure 1:** Known AMPA receptor modulators from different families. Benzamides: (1) aniracetam; 1,2,4-benzothiadiazine 1,1-dioxides: (2) cyclothiazide, (3) diazoxide, (4) IDRA-21, (5) BPAM97, (6) BPAM344, (7) 5-(3-furyl)-IDRA-21,<sup>58</sup> (8) BPAM538; *N*-biarylpropylmethanesulfonamides: dimeric compound (9).




**Figure 2:** Spatial arrangement of two molecules of **5** at the interface of two GluA2 LBDs (left) according to the co-crystallization data.<sup>28</sup> Spatial arrangement of modeled dimeric compound **5** linked with an ethylene bridge at the 6-position of each benzothiadiazine dioxide scaffold [modeled under the SYBYL 8.0 software (Tripos Inc.: St. Louis, MO, 2008) by using a library of standard fragments; the geometry was then optimized using the MMFF94 force field<sup>59</sup>]. It was expected that the dimeric compound can adopt a conformation that fits the two binding sites of the two constitutive monomers.




**Figure 3:** Concentration-response curves obtained in a fluorescence-based calcium assay in GluA2<sub>o</sub>(Q)-transfected HEK293 cells. Compounds **16** and **22** show a marked increase in potency compared to their corresponding monomers (**28** and **34** for **16**; **33** and **35** for **22**).






**Figure 4:** The structure of GluA2<sub>o</sub>-LBD in complex with L-glutamate (Glu) and **16**. (A) Left: side-view of the GluA2<sub>o</sub>-LBD dimer (light green and dark green cartoon representation), showing that **16** (magenta sticks) binds in the lower part of the dimer interface. L-glutamate is shown as grey sticks. Right: a 90° vertically rotated view. (B) Zoom in on the modulator binding site, showing the 2F<sub>o</sub>-F<sub>c</sub> omit electron density map contoured at 1σ and carved at 1.2 Å around the modulator. Residues within 4 Å of **16** and protruding into the binding site are shown in lines. Polar interactions (up to 3.5 Å) of **16** with GluA2<sub>o</sub>-LBD residues and water molecules (red spheres) are shown as stippled, black lines. In addition, water-mediated contacts between Ser518 and Ser750 are shown as red stippled lines. (C) Comparison of the binding mode of **16** and **6** (pdb-code 4N07), showing that **16** and **6** (in beige sticks representation) occupy the same binding sites at the GluA2<sub>o</sub>-LBD dimer interface. The circles indicate the different subsites. GluA2<sub>o</sub> chains belonging to the structure with **16** are shown as cartoon representation.




Reagents: i: methylamine,  $\mu\text{w}$ , yield: 96%; ii:  $\text{KBF}_3\text{CH}=\text{CH}_2$ ,  $\text{Pd}(\text{OAc})_2$ ,  $\text{KF}$ ,  $\mu\text{w}$ , yield: 33%; iii: triethyl orthoformate,  $130^\circ\text{C}$ , yield: 81%; iv:  $\text{NaBH}_4$ , 2-propanol, yield: 61%; v: Hoveyda-Grubbs II catalysts,  $\text{CH}_2\text{Cl}_2$ , yield: 65%; vi:  $\text{Pd/C}$  10%,  $\text{H}_2$ , 12 bars, yield: 25%.

**Scheme 1:** Synthetic pathway leading to the 4-methyl-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide dimeric compound **16**




Reagents: i: cyclopropylamine, 1,4-dioxane,  $\mu\text{w}$ , yield: 75%; ii:  $\text{KBF}_3\text{CH}=\text{CH}_2$ ,  $\text{Pd}(\text{OAc})_2$ ,  $\text{KF}$ ,  $\mu\text{w}$ , yield: 86%; iii: Hoveyda-Grubbs II catalysts,  $\text{CH}_2\text{Cl}_2$ , yield: 89%; iv:  $\text{Pd/C}$  10%,  $\text{H}_2$ , 12 bars, yield: 90%; v: triethyl orthoformate,  $130^\circ\text{C}$ ; yield: 87% vi:  $\text{NaBH}_4$ , 2-propanol, yield: 82%.

**Scheme 2:** Synthetic pathway leading to the 4-cyclopropyl-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide dimeric molecule **22**



Reagents: i: 1:  $\text{ClSO}_2\text{NCO}$ ,  $\text{CH}_3\text{NO}_2$ ; 2:  $\text{AlCl}_3$ ; ii:  $\text{H}_2\text{SO}_4$  50%, yield from **23**: 19%,  $\Delta$ ; iii: triethyl orthoformate,  $130^\circ\text{C}$ , yield: 76%; iv:  $\text{CH}_3\text{I}$ ,  $\text{K}_2\text{CO}_3$ ,  $\text{CH}_3\text{CN}$ , yield: 75%; v:  $\text{NaBH}_4$ , 2-propanol, yield: 75%.

**Scheme 3:** Synthetic pathway leading to the 4,6-dimethyl-substituted BTD monomer **28**




Reagents: i: 1:  $\text{HNO}_2$ ,  $-5^\circ\text{C}$ ; 2:  $\text{SO}_2$ ,  $\text{Cu}_2\text{Cl}_2$ ,  $\text{HOAc}$ ; 3:  $\text{NH}_3$ , yield: 37%; ii: cyclopropylamine, 1,4-dioxane,  $\Delta$ , yield: 35%; iii: triethyl orthoformate,  $130^\circ\text{C}$ , yield: 35%; iv:  $\text{NaBH}_4$ , 2-propanol, yield: 75%.

**Scheme 4:** Synthetic pathway leading to the 4-cyclopropyl-6-methyl-substituted BTD monomer **33**

Tables


**Table 1:** Proposed dimeric structures for the docking studies with their occurrence, ChemPLP score and calculated binding energy (BE)



Numbering	Linker	R	Occurrence <sup>a</sup>	ChemPLP score	BE (kcal/mol)
A or 16	6-(CH <sub>2</sub> ) <sub>2</sub> -6	Methyl	20/20	84.0	-55.7
B or 22	6-(CH <sub>2</sub> ) <sub>2</sub> -6	Cyclopropyl	11/20	90.2	-54.8
C	6-(CH <sub>2</sub> ) <sub>3</sub> -6	Methyl	13/20	87.8	-45.4
D	6-(CH <sub>2</sub> ) <sub>3</sub> -6	Cyclopropyl	10/20	90.1	-53.2
E	6-(CH <sub>2</sub> ) <sub>2</sub> -4	Cyclopropyl	18/20	78.1	-26.9
F	6-(CH <sub>2</sub> ) <sub>2</sub> -4	Cyclopropyl	9/20	81.0	-34.6
G	7-(CH <sub>2</sub> ) <sub>2</sub> -7	Methyl	20/20	85.1	-25.0
H	7-(CH <sub>2</sub> ) <sub>2</sub> -6	Methyl	11/20	78.1	-37.3
I	6-NH-CO-6	Methyl	13/20	61.4	-2.74
J	6-NH-CH <sub>2</sub> -6	Methyl	15/20	81.1	-50.3

<sup>a</sup> The selected docking pose is the best representative (based on the ChemPLP score) of the cluster having the highest occurrence. In this study, the selected docking poses are, in addition, the best docking poses among the 20 solutions given by Gold except for dimeric compounds C and F.

**Table 2:** Potentiating effects of the 3,4-dihydro-2*H*-1,2,4-benzothiadiazine 1,1-dioxide dimeric molecules **16** and **22** compared to the corresponding monomers **28**, **33**, **34** and **35** on the calcium flux induced by 1 mM L-glutamate on HEK293 cells stably expressing the GluA2<sub>o</sub>(*Q*) subunit, and their respective Hill coefficients.



Compounds	pEC <sub>50</sub> <sup>a</sup> [mean ± s.e.m. (n)]	Corresponding EC <sub>50</sub> <sup>b</sup> (μM)	Hill coefficient <sup>c</sup> [mean ± s.e.m. (n)]
<b>34</b>	3.75 ± 0.02 (3)	176.3	2.8 ± 0.4 (3)
<b>28</b>	3.39 ± 0.02 (3)	403.3	2.8 ± 0.4 (3)
<b>16</b>	7.87 ± 0.04 (3)	0.0134	1.2 ± 0.1 (3)
<b>35</b>	5.04 ± 0.02 (3)	9.06	2.2 ± 0.2 (3)
<b>33</b>	4.31 ± 0.03 (3)	48.2	2.2 ± 0.3 (3)
<b>22</b>	8.90 ± 0.05 (3)	0.0014	1.7 ± 0.2 (3)
<b>6</b>	6.090 ± 0.004 (3) <sup>d</sup>	0.81 <sup>d</sup>	3.5 ± 0.1 (3) <sup>d</sup>
<b>8</b>	8.70 ± 0.05 (6) <sup>d</sup>	0.002 <sup>d</sup>	1.4 ± 0.2 (6) <sup>d</sup>

<sup>a</sup> pEC<sub>50</sub>: negative logarithm of the AMPA concentration responsible for 50% of the maximal effect (mean ± s.e.m. (n)). <sup>b</sup> EC<sub>50</sub>: mean concentration responsible for 50% of the maximal effect, in μM. <sup>c</sup> The Hill coefficient is given as the mean value ± s.e.m. (n). <sup>d</sup> Results from Goffin *et al.*<sup>26</sup>

**Table 3:** Crystal data, data collection, and refinement statistics of GluA2<sub>o</sub>-LBD in complex with L-glutamate and **16**.

Crystal Data	
PDB-code	6FAZ
Beamline	BioMAX, MAX-IV
Space group:	P2 <sub>1</sub> 2 <sub>1</sub> 2
Unit cell dimensions (Å)	97.21, 121.46, 47.16
Molecules in a.u. <sup>a</sup>	2
Data collection and processing	
Resolution (Å)	47.16-1.40 (1.47-1.40) <sup>b</sup>
Unique reflections	110,730 (15,969)
Average multiplicity	13.3 (13.4)
Completeness (%)	100 (100)
Wilson B-factor (Å <sup>2</sup> )	16.6
R <sub>merge</sub> (%) <sup>c</sup>	5.5 (64.3)
I/σI	7.2 (1.2)
Refinement	
Numbers of:	
Amino-acid residues (chain A/chain B)	263/260
Compound <b>16</b>	1
L-glutamate/sulfate/PEG/glycerol/chloride/acetate/ethylene glycol/water	2/5/2/5/5/3/2/677
R <sub>work</sub> <sup>d</sup> (%) / R <sub>free</sub> <sup>e</sup> (%)	13.6/16.8
Average B-values (Å <sup>2</sup> ) for	
Amino-acid residues (chain A/chain B)	22.6/26.4
Compound <b>16</b>	26.5
L-glutamate/sulfate/PEG/glycerol/chloride/acetate/ethylene glycol/water	15.6/40.1/43.9/49.2/55.7/38.2/37.8/33.3
RMS deviation bonds length (Å)/angles (deg)	0.007/0.98
Ramachandran outliers/favoured (%) <sup>f</sup>	0/99.1
Rotamer outliers (%) / Cβ outliers (%) / Clash Score	0.8/0/2.54

<sup>a</sup> a.u.: Asymmetric units of the crystal. <sup>b</sup> Values in parentheses correspond to the outermost resolution shell. <sup>c</sup>  $R_{\text{merge}} = \sum_{\text{hkl}} \sum_i |I_{i,\text{hkl}} - I_{\text{hkl}}| / \sum_{\text{hkl}} \sum_i I_{i,\text{hkl}}$ ,  $I_{i,\text{hkl}}$  is the intensity of an individual measurement of the reflection with Miller indices hkl,  $I_{\text{hkl}}$  is the intensity from multiple observations. <sup>d</sup>  $R_{\text{work}} = \sum_{\text{hkl}} (||F_{o,\text{hkl}}| - |F_{c,\text{hkl}}||) / |F_{o,\text{hkl}}|$ , where  $|F_{o,\text{hkl}}|$  and  $|F_{c,\text{hkl}}|$  are the observed and calculated structure factor amplitudes, respectively. <sup>e</sup>  $R_{\text{free}}$  is equivalent to  $R_{\text{work}}$ , but calculated with 5% of the reflections omitted from the refinement process. <sup>f</sup> The Ramachandran plot was calculated according to MolProbity<sup>56</sup>.

## Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI:

.....

Docking studies: proposed structures for docking studies, docking data and modulator-receptor interactions for selected compounds with the dimeric GluA2-LBD-L483Y-N754S, interactions figures for selected compounds with the dimeric GluA2-LBD-L483Y-N754S (PDF).

Molecular formula strings (CSV).

## Accession Codes

PDB : 6FAZ. Authors will release the atomic coordinates and experimental data upon article publication.

## Author information

Corresponding author: Prof. Bernard Pirotte: [b.pirotte@uliege.be](mailto:b.pirotte@uliege.be)

Phone: +32 4 366 43 65. Fax: +32 4 366 43 62

ORCID

B. Pirotte: 0000-0001-8251-8257

Corresponding author on molecular modeling: [lionel.pochet@unamur.be](mailto:lionel.pochet@unamur.be)

Corresponding author on pharmacological evaluation: [j.hanson@uliege.be](mailto:j.hanson@uliege.be)

Corresponding author on structure determination: [jsk@sund.ku.dk](mailto:jsk@sund.ku.dk)

## Acknowledgements

This work was supported by the *Fonds L. Fredericq* from the University of Liege and by the *Fonds National de la Recherche Scientifique* (F.N.R.S.), from which T.D. is a Research Fellow, P.G. is a Télévie Ph.D. Fellow and J.H. is a Research Associate. We also acknowledge funding from The Danish Council for Independent Research/Natural Sciences (S.L., J.S.K.), Danscatt (L.N., S.L., J.S.K.) and CoNeXT (L.N., S.L., J.S.K.). The technical assistance of S. Counerotte (elemental analyses) and H. Peterson (expression, purification and crystallization of GluA2<sub>o</sub>-LBD) is gratefully acknowledged. We would also like to thank beamline scientists at BioMAX, MAX IV, Lund, Sweden for excellent help during data collection.

## Abbreviations

ADHD: attention deficit hyperactivity disorder; AMPA:  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AMPApam: positive allosteric modulator of the AMPA receptor; AMPAR: AMPA receptor; ATD: amino-terminal domain; BBB: blood-brain barrier; BTD: 1,2,4-benzothiadiazine 1,1-dioxide; CNS: central nervous system; CTD: carboxy-terminal domain; DMEM: Dulbecco's Modified Eagle's Medium; DMSO: dimethyl sulfoxide; FBS: bovine fetal serum; GA: generic algorithm; GBMV: Generalized Born with Molecular Volume;



1  
2  
3 HC: Hill coefficient; HBS: Hank's balanced salt; HEK cells: human embryonic kidney cells;  
4  
5 iGluRs: ionotropic glutamate receptors; KA: kainic acid; LBD: ligand-binding domain; mGluRs:  
6  
7 metabotropic glutamate receptors; NMDA: *N*-methyl-D-aspartic acid; NMR: nuclear magnetic  
8  
9 resonance; SAR: structure-activity relationships; TMD: transmembrane domain; TMS:  
10  
11 tetramethylsilane.  
12  
13  
14  
15  
16  
17

## 18 References

- 19  
20 1. Kew, J. N. C.; Kemp, J. A. Ionotropic and Metabotropic Glutamate Receptor Structure  
21  
22 and Pharmacology. *Psychopharmacol.* **2005**, *179*, 4–29.  
23
- 24 2. Traynelis, S. F.; Wollmuth, L. P.; McBain, C. J.; Menniti, F. S.; Vance, K. M., Ogden.  
25  
26 K.K.; Hansen, K. B.; Yuan, H.; Myers, S. J.; Dingledine, R. Glutamate Receptor Ion  
27  
28 Channels: Structure, Regulation, and Function. *Pharmacol. Rev.* **2010**, *62*, 405–496.  
29
- 30 3. Bassani, S.; Valnegri, P.; Beretta, F.; Passafaro, M. The GLUR2 Subunit of AMPA  
31  
32 Receptors: Synaptic Role. *Neuroscience* **2009**, *158*, 55–61.  
33
- 34 4. Bettler, B.; Mülle, C. Review: Neurotransmitter Receptors II. AMPA and Kainate  
35  
36 Receptors. *Neuropharmacology* **1995**, *34*, 123–139.  
37
- 38 5. Kumar, J.; Mayer, M. L. Functional Insights from Glutamate Receptor Ion Channel  
39  
40 Structures. *Annu. Rev. Physiol.* **2013**, *75*, 313–337.  
41
- 42 6. Carlson, G. C. Glutamate Receptor Dysfunction and Drug Targets Across Models of  
43  
44 Autism Spectrum Disorders. *Pharmac. Biochem. Behav.* **2012**, *100*, 850–854.  
45
- 46 7. Chang, P. K. Y.; Verbich, D.; McKinney, R. A. AMPA Receptors as Drug Targets in  
47  
48 Neurological Disease - Advantages, Caveats, and Future Outlook. *Eur. J. Neurosci.* **2012**,  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 35, 1908–1916.

8. Henley, J. M.; Wilkinson, K. A. Synaptic AMPA Receptor Composition in Development, Plasticity and Disease. *Nat. Rev. Neurosci.* **2016**, *17*, 337–350.
9. Kristensen, B. W.; Noraberg, J.; Zimmer, J. Comparison of Excitotoxic Profiles of ATPA, AMPA, KA and NMDA in Organotypic Hippocampal Slice Cultures. *Brain Res.* **2001**, *917*, 21–44.
10. Sobolevsky, A. I. Structure and Gating of Tetrameric Glutamate Receptors. *J. Physiol.* **2013**, *593*, 29–38.
11. Greger, I. H.; Esteban, J. A. AMPA Receptor Biogenesis and Trafficking. *Curr. Opin. Neurobiol.* **2007**, *17*, 289–297.
12. Herguedas, B.; García-Nafria, J.; Cais, O.; Fernández-Leiro, R.; Krieger, J.; Ho, H.; Greger, I. H. Structure and Organization of Heteromeric AMPA-type Glutamate Receptors. *Science* **2016**, *352*, 549–559.
13. Greger, I. H.; Watson, J. F.; Cull-Candy, S. G. Structural and Functional Architecture of AMPA-Type Glutamate Receptors and Their Auxiliary Proteins. *Neuron* **2017**, *94*, 713–730.
14. Sobolevsky, A. I.; Rosconi, M. P.; Gouaux, E. X-ray Structure, Symmetry and Mechanism of an AMPA-subtype Glutamate Receptor, *Nature* **2009**, *462*, 745–756.
15. Weeks, A. M.; Harms, J. E.; Partin, K. M.; Benveniste, M. Functional Insight into Development of Positive Allosteric Modulators of AMPA Receptors. *Neuropharmacology* **2014**, *85*, 57–66.
16. Jin, R.; Clark, S.; Weeks, A. M.; Dudman, J. T.; Gouaux, E.; Partin, K. M. Mechanism of Positive Allosteric Modulators Acting on AMPA Receptors. *J. Neurosci.* **2005**, *25*, 9027–9036.

17. Meyerson, J. R.; Kumar, J.; Chittori, S.; Rao, P.; Pierson, J.; Bartesaghi, A.; Mayer, M. L.; Subramaniam, S. Structural Mechanism of Glutamate Receptor Activation and Desensitization. *Nature* **2014**, *514*, 328–334.
18. Ptak, C. P.; Ahmed, A. H.; Oswald, R. E. Probing the Allosteric Modulator Binding Site of GluR2 with Thiazide Derivatives. *Biochemistry* **2009**, *48*, 8594–8602.
19. Ptak, C. P.; Hsieh, C.-L.; Weiland, G. A.; Oswald, R. E. Role of Stoichiometry in the Dimer-stabilizing Effect of AMPA Receptor Allosteric Modulators. *ACS Chem. Biol.* **2014**, *9*, 128–133.
20. Pirotte B.; Francotte P.; Goffin E.; de Tullio P. AMPA Receptor Positive Allosteric Modulators: a Patent Review. *Expert Opin. Ther. Pat.* **2013**, *2*, 615–628.
21. Schwartz, N.; Torosdag, S.; Fertig, H.; Fletcher, L. Jr; Quan, R. B.; Schwartz, M.S.; Bryant, J. M. Cyclothiazide, a New Diuretic-antihypertensive Drug. *Curr. Ther. Res. Clin. Exp.* **1962**, *4*, 437–440.
22. Bertolino, M.; Baraldi, M.; Parenti, C.; Braghiroli, D.; DiBella, M.; Vicini, S.; Costa, E. Modulation of AMPA/kainate Receptors by Analogues of Diazoxide and Cyclothiazide in Thin Slices of Rat Hippocampus. *Receptors Channels* **1993**, *1*, 267–278.
23. Zivkovic, I.; Thompson, D.M.; Bertolino, M.; Uzunov, D.; DiBella, M.; Costa, E.; Guidotti, A. 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a Benzothiadiazine Derivative that Enhances Cognition by Attenuating DL-alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) Receptor Desensitization. *J. Pharmacol. Exp. Ther.* **1995**, *272*, 300–309.
24. Thompson, D. M.; Guidotti, A.; DiBella, M.; Costa, E. 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a Congener of Aniracetam, Potently

- Abates Pharmacologically Induced Cognitive Impairments in Patas Monkeys. *Proc. Natl. Acad. Sci. U. S. A.* **1995**, *92*, 7667–7671.
25. Pirotte, B.; Francotte, P.; Goffin, E.; Fraikin, P.; Danober, L.; Lesur, B.; Botez, I.; Caignard, D. H.; Lestage, P.; de Tullio, P. Ring-fused Thiadiazines as Core Structures for the Development of Potent AMPA Receptor Potentiators. *Curr. Med. Chem.* **2010**, *17*, 3575–3582.
26. Goffin, E.; Drapier, T.; Probst Larsen, A.; Geubelle, P.; Ptak, C. P.; Laulumaa, S.; Rovinskaja, K.; Gilissen, J.; de Tullio, P.; Olsen, L.; Frydenvang, K.; Pirotte, B.; Hanson, J.; Oswald, R. E.; Kastrup, S. J.; Francotte, P. 7-Phenoxy-Substituted 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxides as Positive Allosteric Modulators of  $\alpha$ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors with Nanomolar Potency. *J. Med. Chem.* **2018**, *61*, 251–264.
27. Kaae, B. H.; Harpsøe, K.; Kastrup, J. S.; Sanz, A. C.; Pickering, D. S.; Metzler, B.; Clausen, R. P.; Gajhede, M.; Sauerberg, P.; Liljefors, T.; madsen, U. Structural Proof of a Dimeric Positive Modulator Bridging Two Identical AMPA Receptor-Binding Sites. *Chem. Biol.* **2007**, *14*, 1294–1303.
28. Krintel, C.; Frydenvang, K.; Olsen, L.; Kristensen, M. T.; de Barrios, O.; Naur, P.; Francotte, P.; Pirotte, B.; Gajhede, M.; Kastrup, J. S. Thermodynamics and Structural Analysis of Positive Allosteric Modulation of the Ionotropic Glutamate Receptor GluA2. *Biochem. J.* **2012**, *441*, 173–178.
29. Nørholm, A.-B.; Francotte, P.; Olsen, L.; Krintel, C.; Frydenvang, K.; Goffin, E.; Challal, S.; Danober, L.; Botez-Pop, I.; Lestage, P.; Pirotte, B.; Kastrup, J. S. Synthesis, Pharmacological and Structural Characterization, and Thermodynamic Aspects of

- GluA2-Positive Allosteric Modulators with a 3,4-Dihydro-2*H*-1,2,4-benzothiadiazine 1,1-Dioxide Scaffold. *J. Med. Chem.* **2013**, *56*, 8736–8745.
30. Francotte, P.; Nørholm, A. B.; Deva, T.; Olsen, L.; Frydenvang, K.; Goffin, E.; Fraikin, P.; de Tullio, P.; Challal, S.; Thomas, J.-Y.; Iop, F.; Louis, C.; Botez-Pop, I.; Lestage, P.; Danober, L.; Kastrup, J.S.; Pirotte, B. Positive Allosteric Modulators of 2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic Acid Receptors Belonging to 4-Cyclopropyl-3,4-dihydro-2*H*-1,2,4-pyridothiadiazine Dioxides and Diversely Chloro-substituted 4-Cyclopropyl-3,4-dihydro-2*H*-1,2,4-benzothiadiazine 1,1-Dioxides. *J. Med. Chem.* **2014**, *57*, 9539–9553.
31. Nørholm, A. B.; Francotte, P.; Goffin, E.; Botez, I.; Danober, L.; Lestage, P.; Pirotte, B.; Kastrup, J. S.; Olsen, L.; Oostenbrink, C. Thermodynamic Characterization of New Positive Allosteric Modulators Binding to the Glutamate Receptor A2 Ligand-binding Domain: Combining Experimental and Computational Methods Unravels Differences in Driving Forces. *J. Chem. Inf. Model.* **2014**, *54*, 3404–3416.
32. Larsen, A. P.; Francotte, P.; Frydenvang, K.; Tapken, D.; Goffin, E.; Fraikin, P.; Caignard, D. H.; Lestage, P.; Danober, L.; Pirotte, B.; Kastrup, J. S. Synthesis and Pharmacology of Mono-, Di-, and Trialkyl-Substituted 7-Chloro-3,4-dihydro-2*H*-1,2,4-benzothiadiazine 1,1-Dioxides Combined with X-ray Structure Analysis to Understand the Unexpected Structure-Activity Relationship at AMPA Receptors. *ACS Chem. Neurosci.* **2016**, *7*, 378–390.
33. Krintel, C.; Francotte, P.; Pickering, D. S.; Juknaitė, L.; Pøhlsgaard, J.; Olsen, L.; Frydenvang, K.; Goffin, E.; Pirotte, B.; Kastrup, J. S. Enthalpy-Entropy Compensation in the Binding of Modulators at Ionotropic Glutamate Receptor GluA2. *Biophys. J.* **2016**, *110*, 2397–2406.

34. Francotte, P.; de Tullio, P.; Goffin, E.; Dintilhac, G.; Graindorge, E.; Fraikin, P.; Lestage, P.; Danober, L.; Thomas, J-Y.; Caignard D.-H.; Pirotte, B. Design, Synthesis, and Pharmacology of Novel 7-Substituted 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxides as Positive Allosteric Modulators of AMPA Receptors. *J. Med. Chem.* **2007**, *50*, 3153–3157.
35. Girard, Y.; Atkinson, J. G.; Rokach, J. A New Synthesis of 1,2,4-Benzothiadiazines and a Selective Preparation of *o*-Aminobenzenesulphonamides. *J. Chem. Soc. Perkin Trans. 1* **1979**, 1043–1047.
36. Meerwein, H.; Dittmar, G.; Göllner, R.; Hafner, K.; Mensch, F.; Steinfort, O. Untersuchungen über aromatische Diazoverbindungen, II. Verfahren zur Herstellung Aromatischer Sulfonsäurechloride, Eine Neue Modifikation der Sandmeyerschen Reaktion. *Chem. Ber.* **1957**, *90*, 841–852.
37. Varney, M. A.; Rao, S. P.; Jachec, C.; Deal, C.; Hess, S. D.; Daggett, L. P.; Lin, F.-F.; Johnson, E. C.; Veliçelebi, G. Pharmacological Characterization of the Human Ionotropic Glutamate Receptor Subtype GluR3 Stably Expressed in Mammalian Cells. *J. Pharmacol. Exp. Ther.* **1998**, *285*, 358–370.
38. Weiss, J.N. The Hill Equation Revisited: Uses and Misuses. *FASEB J.* **1997**, *11*, 835–841.
39. Priel, A.; Selak, S.; Lerma, J.; Stern-Bach, Y. Block of Kainate Receptor Desensitization Uncovers a Key Trafficking Checkpoint. *Neuron* **2006**, *52*, 1037–1046.
40. Weston, M. C.; Schuck, P.; Ghosal, A.; Rosenmund, C.; Mayer, M. L. Conformational Restriction Blocks Glutamate Receptor Desensitization. *Nat. Struct. Mol. Biol.* **2006**, *13*, 1120–1127.


41. Armstrong, N.; Jasti, J.; Beich-Frandsen, M.; Gouaux, E. Measurement of Conformational Changes accompanying Desensitization in an Ionotropic Glutamate Receptor. *Cell* **2006**, *127*, 85–97.
42. Pøhlsgaard, J.; Frydenvang, K.; Madsen, U.; Kastrup, J.S. Lessons from more than 80 Structures of the GluA2 Ligand-Binding Domain in Complex with Agonists, Antagonists and Allosteric Modulators. *Neuropharmacology* **2011**, *60*, 135–150.
43. Topliss, J. G.; Sherlock, M. H.; Leroy, H. R.; Konzelman, L. M.; Shapiro, E. P.; Pettersen, B. W.; Schneider, H.; Sperber, N. Antihypertensive agents. I. Nondiuretic 2H-1,2,4-benzothiadiazine 1,1-dioxides. *J. Med. Chem.* **1963**, *6*, 122–127.
44. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking. *J. Mol. Biol.* **1997**, *267*, 727–748.
45. Sakkiiah, S.; Arooj, M.; Kumar, M. R.; Eom, S. H.; Lee, K. W. Identification of Inhibitor Binding Site in Human Sirtuin 2 Using Molecular Docking and Dynamics Simulations. *PLoS ONE* **2013**, *8*, e51429.
46. Tirado-Rives, J.; Jorgensen, W. L. Contribution of Conformer Focusing to the Uncertainty in Predicting Free Energies for Protein-ligand Binding, *J. Med. Chem.* **2006**, *49*, 5880–5884.
47. Krintel, C.; Frydenvang, K.; Ceravalls de Rabassa, A.; Kaern, A. M.; Gajhede M.; Pickering, D. S.; Kastrup, J. S. L-Asp is a Useful Tool in the Purification of the Ionotropic Glutamate Receptor A2 Ligand-Binding Domain. *FEBS J.* **2014**, *281*, 2422–2430.
48. Kabsch, W. XDS. *Acta Crystallogr. D Biol. Crystallogr.* **2010**, *66*, 125–132.
49. Evans, P.R. An Introduction to Data Reduction: Space-Group Determination, Scaling and Intensity Statistics. *Acta Crystallogr. D Biol. Crystallogr.* **2011**, *67*, 282–292.

50. Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.; Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S. Overview of the CCP4 Suite and Current Developments. *Acta Crystallogr. D Biol. Crystallogr.* **2011**, *67*, 235–242.
51. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser Crystallographic Software. *J. Appl. Crystallogr.* **2007**, *40*, 658–674.
52. Terwilliger, T. C.; Grosse-Kunstleve, R. W.; Afonine, P. V.; Moriarty, N. W.; Zwart, P. H.; Hung, L.-W.; Read, R. J.; Adams, P. D. Iterative Model Building, Structure Refinement and Density Modification with the PHENIX AutoBuild Wizard. *Acta Cryst.* **2008**, *D64*, 61–69.
53. Adams, P. D.; Afonine, P. V.; Bunkóczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L. W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a Comprehensive Python-Based System for Macromolecular Structure Solution. *Acta Crystallogr. D Biol. Crystallogr.* **2010**, *66*, 213–221.
54. Moriarty, N. W.; Grosse-Kunstleve, R. W.; Adams, P. D. Electronic Ligand Builder and Optimization Workbench (eLBOW): a Tool for Ligand Coordinate and Restraint Generation. *Acta Crystallogr. D Biol. Crystallogr.* **2009**, *65*, 1074–1080.
55. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and Development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **2010**, *66*, 486–501.
56. Davis, I. W.; Leaver-Fay, A.; Chen, V. B.; Block, J. N.; Kapral, G. J.; Wang, X.; Murray, L. W.; Arendall, W. B.; Snoeyink, J.; Richardson, J. S.; Richardson, D. C. MolProbity:



- All-Atom Contacts and Structure Validation for Proteins and Nucleic Acids. *Nucl. Acids Res.* **2007**, *35*, W375–W383.
57. Hayward, S.; Berendsen, H. J. C., Systematic Analysis of Domain Motions in Proteins from Conformational Change; New Results on Citrate Synthase and T4 Lysozyme *Proteins, Structure, Function and Genetics* **1998**, *30*, 144–154.
58. Battisti, U. M.; Jozwiak, K.; Cannazza, G.; Puia, G.; Stocca, G.; Braghiroli, D.; Parenti, C.; Brasili, L.; Carrozzo, M. M.; Citti, C.; Troisi, L. 5-Arylbenzothiadiazine Type Compounds as Positive Allosteric Modulators of AMPA/Kainate Receptors. *ACS Med. Chem. Lett.*, **2012**, *3*, 25–29.
59. Halgren, T. A. Merck Molecular Force Field. I. Basis, Form, Scope, Parameterization, and Performance of MMFF94. *J. Comput. Chem.* **1996**, *17*, 490–519.

Table of Content Graphic



AMPA receptor potentiator effect  
on HEK293 cells expressing GLUA2<sub>o</sub>(Q)

